The Institute of Cancer Research shared a post on LinkedIn:
“BREAKING:
Researchers at the ICR have shown that pembrolizumab, an immunotherapy drug, helps head and neck cancer patients live years longer cancer-free.
The immunotherapy also hunts down cancer trying to spread – after three years, the risk of cancer returning elsewhere in the body was 10 per cent lower than for patients on standard treatment. The phase III KEYNOTE-689 trial was led by University of Washington – School of Medicine, USA and funded by MSD.
Read about the results of the trial, presented at the American Society of Clinical Oncology annual meeting.”